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Abstract
For a long time, cartilage has been a major focus of the whole field of tissue engineering, both because of the
constantly growing need for more effective options for joint repair and the expectation that this apparently simple
tissue will be easy to engineer. After several decades, cartilage regeneration has proven to be anything but easy.
With gratifying progress in our understanding of the factors governing cartilage development and function, and
cell therapy being successfully used for several decades, there is still a lot to do. We lack reliable methods to
generate durable articular cartilage that would resemble the original tissue lost to injury or disease. The question
posed here is whether the answer would come from the methods using cells, biomaterials, or tissue engineering.
We present a concise review of some of the most meritorious efforts in each area, and propose that the solution
will most likely emerge from the ongoing attempts to recapitulate certain aspects of native cartilage development.
While an ideal recipe for cartilage regeneration is yet to be formulated, we believe that it will contain cell,
biomaterial, and tissue engineering approaches, blended into an effective method for seamless repair of articular
cartilage.
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Background
Articular cartilage is a unique tissue that contains only a
sparse population of a single cell type—chondrocyte—and
lacks vascularization. The cells reside within a prestressed
collagen–proteoglycan matrix that gives the tissue its com-
pressive strength and enables frictionless motion during
habitual loading. These features also severely hinder the
ability of cartilage to regenerate after injury. Whether the
injury is due to trauma or disease, and even if the lesion is
relatively small, it can progress rapidly and lead to the
destruction of cartilage structure and thereby its mechan-
ical function. Because of the absence of self-repair, various
interventions have been explored to facilitate regeneration
of cells and cartilaginous matrix.
Traditionally, cartilage repair has been pursued by
application of two main treatment methods, both of
which have drawbacks. If cartilage is severely damaged
so that the majority of the articulating surface is
disabled, whole joint surgery can be performed where
the living biological tissue is replaced with a prosthetic
device. While these surgeries are quite successful and
provide many years of joint function, the synthetic ma-
terial cannot fully substitute for the complex biological
nature of the original tissue. If cartilage injury is small
and localized, an autograft or allograft can be trimmed
to size and fit into the defect. However, with the cartil-
age properties being location dependent and because of
the scarcity of cells that can facilitate graft integration
with the host tissues, these grafting solutions often pro-
vide a limited-term benefit before ultimately failing [1].
A definite need therefore exists for more effective
methods to stimulate cartilage regeneration and integra-
tion, and provide a durable, long-lasting replacement for
the original cartilage.
In response to this need, novel bioengineering ap-
proaches to induce and enhance cartilage regeneration
are being developed. When placed into the context of
natural cartilage development, these approaches are
based on achieving different landmarks in the process of
cartilage formation, with the aim to recapitulate the
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developmental blueprints [2]. It is well established that
cartilage formation begins with mesenchymal condensa-
tion leading to chondrogenic differentiation of mesen-
chymal cells. Then, a dense matrix is produced, serving
as the cartilage anlage, a template for the subsequent
generation of both the articular cartilage and the sub-
chondral bone. The articular chondrocytes maintain
their stable phenotype within mature articular cartil-
age (Fig. 1).
Scientists and engineers have attempted to develop
biological grafts for treating cartilage defects by (i) cell
therapies that recapitulate precartilaginous mesenchymal
condensation and stimulate/orchestrate regeneration of
cartilage, (ii) biomaterial matrices designed to restore
important functions of articular cartilage and serve as a
template for regenerative turnover, or (iii) tissue-engi-
neered grafts for implantation that resemble mature
cartilage and have capacity to integrate with the sur-
rounding tissues [3, 4]. In this concise review, we present
a brief survey of the merits of current research for each
of these three approaches to cartilage regeneration,
along with the status of their translation into the clinic,
towards an initial response to the question posed about
the prospects of using cells, biomaterials, or tissue en-
gineering for cartilage regeneration.
Cell therapies
Cells are the driving force of cartilage formation and the
continual maintenance of the tissue. Cell therapies utilize
the implantation of externally cultivated cells to replicate
and stimulate native regeneration. Mature chondrocytes
were the first cells that found clinical application for cartil-
age regeneration. Similar to autografts and allografts,
the use of mature chondrocytes is based on the
premise that native, mature cells are best suited to
guide regeneration.
Mature chondrocytes in cell therapy applications have
been primarily utilized in a technique termed autologous
chondrocyte implantation (ACI). ACI starts by harvesting
and enzymatically isolating chondrocytes from a minor
load-bearing area of the patient’s damaged cartilage [5].
As cartilage has low cell density, the isolated chondrocytes
have to be expanded in vitro to obtain enough cells for ef-
fective treatment. In ACI therapy, a membrane is placed
over the defect that is filled with a suspension of chondro-
cytes and sutured to the surrounding cartilage to ensure
chondrocyte localization within the defect [6]. Initially, a
piece of periosteum cut out from the patient’s bone was
used as a membrane, probably further contributing to car-
tilage regeneration as an additional source of cells. Later,
synthetic membranes made of a collagen I/III blend were
also used.
While the clinical trials reported good-to-excellent
outcomes for almost all of the patients at 66 months,
further randomized clinical trials demonstrated that ACI
performed no better than microfracture surgeries [7].
Some limitations were also observed. When expanded
on plastic in vitro, harvested articular chondrocytes tend
to dedifferentiate and start producing substantial amounts
of collagen type I. Such expansion and dedifferentiation
can hinder hyaline cartilage formation and result in
hypertrophic chondrocyte differentiation when im-
planted back into the defect [8]. Consequently, it has
been noted that the cartilage formed following a
traditional ACI procedure tends to histologically re-
semble fibrocartilage rather than articular cartilage [1].
Fig. 1 Chondrogenic development. (1) Mesenchymal condensation. (2) Chondrogenic differentiation of mesenchymal cells and deposition of a
cartilage anlage that forms both cartilage and bone. (3) Remodeling of the anlage to form bone and mature cartilage with their inherent
structural zones. Cartilage regeneration therapies have followed this approach, having investigated cellular therapies to trigger cartilage formation,
biomaterial scaffolds that infiltrating cells can remodel, and tissue-engineered cartilage constructs that mimic the structure and function of native
articular cartilage
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Fibrocartilage is a dense, fibrous version of cartilage, lack-
ing the compressive strength and frictionless properties of
hyaline cartilage. The presence of fibrocartilage causes
similar problems to the transplantation of articular cartil-
age autografts, where a lack of integration and mismatch
in functional properties limit complete regeneration of the
defect. Over the years, ACI has undergone numerous im-
provements [9], which have moved the ACI procedure
from being classified as a cell therapy towards being a
tissue-engineering therapy.
The use of mesenchymal stem cells (MSC) can alleviate
two fundamental limitations of autologous chondrocytes:
donor-site morbidity and limited matrix production fol-
lowing cell expansion. MSCs can be harvested from a
number of sources that do not affect cartilage activity (a
complete list is provided in [10]), maintain multipotency
after numerous expansions, and can be differentiated
into matrix-producing chondrocytes [11]. In addition,
MSCs have immunomodulatory properties and have
been shown to suppress proinflammatory cytokines
[12]. However, it is currently being debated whether
chondrogenically differentiated MSCs are programmed
to progress towards terminal differentiation and bone
formation [13, 14]. Primarily due to their favorable
properties, and despite the current debate, MSCs are
increasingly studied and utilized to treat cartilage de-
fects and osteoarthritis [10].
For cartilage defects, the application of MSCs is similar
to the ACI method, and has produced similar results. In a
comparison of the procedures based on ACI and MSCs,
there was no significant difference in the clinical outcome
[15]. While the results of the ACI-type therapy using
MSCs are promising, problems similar to those observed
in the traditional ACI treatment still persist. Importantly,
MSCs are a heterogeneous cell population that can gener-
ate fibrocartilage and hypertrophic chondrocytes along
with the desired articular-cartilage-producing chondro-
cytes [16]. Studies have shown nonarticular cartilage being
formed within the defect after implantation, and this situ-
ation was associated with poor clinical outcomes [17].
In attempts to more consistently derive articular chon-
drocytes that produce matrix and regenerate cartilage,
investigators have turned to pluripotent stem cell sources:
embryonic stem cells (ESCs) and induced pluripotent
stem cells (iPSCs). While the use of ESCs is highly
debated because of the ethics surrounding their deriv-
ation, iPSCs provide similar pluripotency without the eth-
ical conundrum. In addition, iPSCs can be autologous as
they can be derived from small samples of various tissues,
including skin and blood. The derivation of chondrocytes
from ESCs or iPSCs can be achieved by first deriving
MSCs [18, 19], or by differentiating the cells directly into
chondrocytes [20, 21]. Overall, the use of pluripotent stem
cells for cartilage regeneration is highly promising. In
comparison with MSC-derived chondrocytes, chondro-
cytes differentiated from pluripotent stem cells had higher
gene expression for chondrocyte and cartilage-producing
genes (COL2A1, AGC, SOX9), and reduced expression of
hypertrophic and bone-producing genes (COL10A1,
COL1A1, RUNX2) [22]. Numerous studies have shown
the ability of these cells to produce articular-like cartilage
that integrated with the native cartilage and subchondral
bone when implanted into an animal defect [9, 22–24].
The ability of pluripotent stem cells to differentiate
into all three germ layers and recapitulate the native,
cartilage-producing cell phenotype is highly attractive
for cartilage regeneration, but key challenges exist in
efficiently producing and safely controlling these cells.
Although recent advances have improved the efficiency
of iPSC generation [25], the yields remain low for mass
production. Also, the implantation of pluripotent stem
cells has occasionally resulted in teratoma formation [26,
27]. Studies have shown that genetic disorders, such as
Marfan’s syndrome, still manifest in derived chondro-
cytes, even after the induction of pluripotency and sub-
sequent in-vitro differentiation [28]. Despite promising
results in stimulating cartilage regeneration, the pluripo-
tent stem cell generation, the inability to recover genetic
deficiency, and the risk of teratoma formation pose sig-
nificant questions that must be addressed before clinical
translation.
While major progress has been made using each of
the cell types discussed, it is still being investigated how
to overcome the current limitations and produce viable,
functional, and durable cartilage capable of integrating
with the surrounding tissues. Clinical trials of cartilage
therapies using pluripotent stem cells (either embryonic
or derived from adult human tissues) have been slowed
down by concerns that multipotent stem cells have po-
tential to form teratomas [9]. In clinical practice, ACI is
a well-established cell therapy for cartilage repair, with
variations of the procedure used in the clinic since
1987, and numerous revisions and improvements [29].
The use of MSCs for cartilage therapy is currently
undergoing the rigors of regulatory approval, with the
first clinical study performed in 2004 [10], providing
cartilage repair without the need to harvest chondro-
cytes from the patient.
Biomaterials
Because of the seemingly quiescent nature of cartilage,
its avascularity, and its low cell density (only about 5 %
of the tissue volume), a significant branch of research
has been directed towards developing biomaterials that
can mimic cartilage matrix and restore function at the
defect site. In particular, the biomaterials of choice must
meet three significant criteria: (i) mechanical properties
consistent with those of existing cartilage (both in terms
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of compressive strength and lack of friction), (ii) inte-
gration with adjacent cartilage, and (iii) durability
throughout the patient’s lifetime [30]. Currently used
biomaterials are in general biodegradable, with the goal
that the biomaterial will eventually be eliminated from
the body after providing the necessary functional proper-
ties to support cartilage regeneration. For many mate-
rials, the rate and mechanisms of biodegradation are
tunable, which is important for matching the kinetics of
biomaterial resorption and tissue formation.
Up to 80 % of articular cartilage wet weight consists of
water, its most abundant component [31]. To replicate
this environment, hydrogels—three-dimensional (3D)
polymer networks rich in water—have become a popular
option for cartilage regeneration in situ and cartilage
engineering in vitro. Hydrogels are highly modular, with
respect to the type of polymer, the crosslinking method,
the degradation products and rate, and the incorporation
of various molecules, all allowing specific tailoring for
the desired application [32, 33]. Hydrogels are classified
based on the polymer composition into natural or syn-
thetic materials, although combination systems are also
being used to maximize the benefits of each component.
We will briefly touch on the most popular polymers
from each group.
Natural polymers can be derived from both animal
and plant sources. Three of the most popular polymers
that are used as hydrogels are alginate, agarose, and silk,
with the first two derived from seaweed and the last
derived from either silkworms or spiders [32]. The unique
composition of these polymers makes them unrecognizable
to human enzymes, allowing slow degradation and more
time for the body to initiate and support regeneration
[32]. The mechanical properties of these hydrogels can
be adjusted using the right formulations and postpro-
cessing methods [33]. In addition, these hydrogels have
been shown in vitro to provide suitable environments to
maintain the phenotype of encapsulated chondrocytes.
However, these particular hydrogels lack natural attach-
ment sites for cells and inherent bioactivity to trigger
synthesis of extracellular matrix (ECM) [23, 34].
Although readily available, semicustomizable, and easy
to work worth, the ability of these scaffolds to stimulate
regeneration and integrate in an in-vivo repair situation
is yet to be determined conclusively.
Collagen and hyaluronan are the two popular natural
polymers that are recognizable by mammalian cells and, at
the same time, are important components of native articu-
lar cartilage. Collagen, as the most common protein in the
body, has been extensively studied for cartilage regeneration
[35]. Collagen has a natural tendency to support cell attach-
ment and stimulate synthesis and assembly of the ECM.
However, when implanted, collagen hydrogels are mechan-
ically weaker than the surrounding tissue and degrade too
fast relative to tissue regeneration [36, 37]. Crosslinking of
the collagen matrices can improve their mechanical integ-
rity and slow down degradation, but it also can have signifi-
cant impact on the encapsulated cells [38].
In native cartilage, chondrocytes surround themselves
with a hyaluronan-based pericellular matrix, which has
led many investigators to designing hydrogels consisting
of hyaluronan [39]. As expected, chondrocytes readily
attach to hyaluronan-based matrices, and studies have
shown that these matrices trigger chondrocyte differenti-
ation and stimulate matrix production [40, 41]. Hyaluronan
also has some limitations, such as insufficient mechanical
integrity and a short lifetime in inflamed defects due to
degradation by matrix metalloproteinases [42].
In contrast to natural polymers, synthetic polymers pro-
vide a high level of control of compositional, structural, and
mechanical properties. Polyglycolic acid (PGA) and polylac-
tic acid (PLA) have gained particular interest because they
degrade by simple hydrolysis at rates that can be adjusted
by selecting monomers, and have already been approved
for clinical use as sutures [43]. A major drawback of
synthetic polymers is that they do not provide specific
biological functions [44]. To facilitate cell attachment
and stimulate matrix production, the synthetic poly-
mers need to be functionalized with biological motifs
or bioactive molecules [45].
Polymer modifications are widely utilized to control cell
activities within the body. Of particular interest are efforts
to recruit native cells and promote their differentiation
and regenerative capabilities [43, 46]. The incorporation
of growth factors and biomolecules, such as dexametha-
sone and transforming growth factor beta, has shown
promise for facilitating cartilage regeneration [47, 48].
Such functionalized scaffolds release the incorporated
modulatory components as they are degraded, and can
thereby enhance cartilage regeneration within a defect.
However, this interesting approach has not been fully real-
ized, and the degree of regeneration achieved thus far has
not been convincing enough to justify clinical translation.
An important trend in surgery, both general and
orthopedic, is to minimize the severity of intervention
[49]. The use of an arthroscopic procedure instead of
open joint surgery can reduce the infection risk and
shorten the time of recovery. For cartilage repair, the use
of injectable hydrogels is of special interest because they
are compatible with arthroscopic methods. By introdu-
cing the regenerative hydrogel into the defect by injec-
tion through the joint capsule, procedural severity and
duration as well as the duration of recovery are reduced
significantly [49]. Many of these polymers have been
transitioned into injectable formats. The two most com-
mon forms of initiating the transition from injectable
liquid to hydrogel are thermal activation, which results
in the crosslinking of hydrogel at body temperature, and
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light activation, which initiates crosslinking of hydrogel
in the presence of a specific light source [44, 50, 51].
Beyond any doubt, biomaterials will continue to be a
major focus of research for cartilage regeneration. For
clinical purposes, biomaterials are extremely attractive
because they can be utilized off-the-shelf, have an
established precedence of clinical use, and have much
simpler and shorter regulatory procedures than cell-
based products.
Tissue engineering
The incorporation of cells into biomaterial scaffolds makes
cartilage repair more complex, but can significantly help
orchestrate regeneration and overcome some of the limi-
tations of using cells or biomaterials alone. After several
decades of research in cartilage regeneration, either
through cell therapy or biomaterial implantation, we still
lack robust methods for reestablishing durable articular
surfaces with mature functional tissue properties. In an
effort to address this major challenge, scientists and engi-
neers turned to tissue engineering methods designed to
replicate the developmental steps of cartilage formation.
In general, tissue engineering combines cells and bioma-
terial scaffolds into a tissue construct, and then uses engi-
neered control of the construct environment, in vitro and
in vivo, to replicate the native cartilage environment and
produce viable grafts for cartilage regeneration [52].
Here we focus on the inclusion of additional, external
engineered controls to create these cartilage constructs.
Mechanical stimulation, oxygen tension, and 3D print-
ing are among the methods that have been utilized to
replicate the in-vivo environment supporting chondro-
cyte differentiation and matrix production.
Articular cartilage is subjected to cyclic forces and the
application of physiological levels and regimens of stress
is considered to be essential for chondrocyte viability
and function [53]. To replicate this environment, com-
pressive forces were applied to tissue-engineered con-
structs during in-vitro cultivation. Specially designed
bioreactors were constructed that allowed control of the
rate and amplitude of the applied stress [53]. Dynamic
mechanical compression has been shown to trigger chon-
drocyte differentiation [45], stimulate matrix production
[54], and increase cell viability and proliferation [23].
These beneficial effects are presumably due to a combin-
ation of direct mechanical factors (and their transduction
into gene expression) and enhancement of mass transport
by compression-induced interstitial flow. Constructs that
were conditioned within bioreactors with mechanical
loading approached more closely the compressive proper-
ties of native cartilage, as the application of force dictated
the location and alignment of matrix deposition by resi-
dent chondrocytes [55, 56]. The application of compres-
sive forces to the tissue-engineered construct could be
utilized to mature and strengthen the graft, signaling the
chondrocytes to replicate a cartilage-mimicking structure.
Studies of the dynamic environment of cartilage revealed
that the individual chondrocytes did not actually experience
direct compressive stress, but rather a hydrostatic pressure
caused by the swelling and fluid movement associated with
the articular cartilage loading [53]. Hydrostatic bioreactors
were therefore constructed to replicate the in-vivo environ-
ment in a loaded joint [57], producing similar results to
those achieved in response to compressive loading. Both
the chondrocytes and MSCs expressed higher levels of car-
tilage genes and produced larger amounts of glycosamino-
glycans and type II collagen [58, 59].
The environment of healthy cartilage is hypoxic, with
oxygen tensions ranging between 1 and 5 %, as com-
pared with 21 % in ambient air [53]. However, traditional
tissue culture is in most cases carried out in normoxic
conditions. Lowering oxygen tension has enhanced MSC
and chondrocyte differentiation and arrested hyper-
trophic maturation [60–62]. There is still a debate about
the degree of ECM synthesis stimulated by hypoxia, as
conflicting reports have been published on both sides of
the argument [63]. However, as has been shown with
both the mechanical stimulation and oxygen tension,
replicating the native environmental conditions of cartil-
age has beneficial effects on engineered cartilage.
3D printing has also gained a considerable amount of at-
tention due to its ability to provide precise control of the
initial structure of tissue-engineered constructs. While
other processing methods have been used previously to
mimic the structure of native cartilage [64], the novelty of
3D printing and the high degree of precision (almost to
the cellular level) are the focus in this review. An excellent
recent review by Garg and Goyal [64] covers the broad
scope of fabrication processes. With regards to cartilage,
ongoing work indicates that 3D printing has the potential
to replicate the specific structure of cartilage, depositing
an appropriate pericellular environment for the cells lo-
cated in each cartilage zone [65–67]. The most successful
studies to date have recapitulated an osteochondral defect,
using different substrates and patterns for bone and cartil-
age components [68, 69]. Bioprinting directly into a cre-
ated, ex-vivo cartilage defect resulted in some level of
integration into the native cartilage and mechanical com-
petence [70].
Despite the increased ability of tissue engineering to
mimic the native environment and enhance cartilage
matrix production, current tissue constructs are still not
stratified and mechanically functional, and therefore are
not suitable for clinical use [71]. Carticel, a longstanding
tissue-engineered product, has resulted in the develop-
ment of articular cartilage that integrated with the adja-
cent native cartilage. However, this method requires
harvesting the chondrocytes from the patient’s knee,
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resulting in tissue morbidity and the need for two surger-
ies. In contrast, MSCs from bone marrow or fat aspirates
are much easier to harvest, can be expanded in culture,
and can be differentiated into chondrocytes. However,
stratified structure and mechanical function have not been
achieved with these cells. Interestingly, the work by
Mauck et al. [72] shows that these limitations are not a re-
sult of delayed cell differentiation, but are due to a missing
link in the development of cartilage tissue-engineered
constructs.
A novel approach that appears to find this missing link
recapitulates important steps in the native development of
cartilage (Fig. 2). In these studies, chondrocytes and stem
cells were condensed into scaffold-less constructs that
formed cartilaginous tissue in a manner mimicking mesen-
chymal condensation that precedes native chondrogenesis
[73–76]. This condensation-based approach demonstrated
promising results, with studies revealing structural similar-
ity of the tissue-engineered construct to native cartilage
[73–76]. In one approach, biomechanical properties of
cartilage derived from condensed human mesenchymal
cells were comparable with native cartilage, with Young’s
modulus of approximately 850 kPa and equilibrium friction
coefficient <0.3. This method also formed mechanically
strong cartilage and an interface in a cartilage defect model
[73]. The mimicking of native development of cartilage
with application of external controls provides an enticing
way forward in the elusive pursuit of a translatable
cartilage-defect solution.
Conclusions
We still lack reliable methods to generate durable articu-
lar cartilage that would resemble the original tissue lost
to injury or disease. For clinical translation, a product
that is available off-the-shelf, can be applied without sur-
gery, integrates seamlessly into the native cartilage, and
incorporates native cells to allow remodeling would be
most highly desired. Basic and translational studies con-
ducted over the last several decades markedly advanced
our understanding of cartilage development, normal
function, and pathological function.
Cartilage has proven to be both simple (with its sparse
population of a single cell type, absence of vascular sup-
ply) and very complex (as its prestressed matrix and
Fig. 2 Engineering of stratified, mechanically functional human cartilage. a Human mesenchymal stem cells are induced to fuse into cell bodies which
are then placed on the cartilage side of a mold in the exact shape of a condyle, an anatomically shaped bone scaffold is placed on the other side, and
the two pieces are press-fit. After 5 weeks of in-vitro cultivation, an anatomical layer of articular cartilage forms at the interface with the underlying
bone. b The resulting cartilage is physiologically thick and stratified, expressing all key markers, and integrated with the underlying bone. c The fusing
mesenchymal stem cell bodies were also tested for their ability to repair small cartilage defects. Structural integration is shown by alcian blue
and antibody stains for glycosaminoglycan and collagen type II. The newly formed tissue is shown on the left, the adjacent native cartilage on
the right. Selected images are reproduced with permission from [73]. H & E hematoxylin and eosin
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its structural and mechanical properties are rather difficult
to engineer). The question posed here is whether cartilage
regeneration will be achieved using cells alone, or bioma-
terials, or tissue engineering. We propose that the ultimate
therapeutic modalities will actually combine the best ele-
ments of all three approaches. We also propose that the
overriding principle for the development of effective clin-
ical modalities will be in the recapitulation of some of the
key steps in native cartilage development, such as the early
steps of mesenchymal condensation and the development
of cartilage anlage. The simplest and most robust method
for achieving durable cartilage repair will certainly have
the highest chance of clinical acceptance. The field will
need to determine how simple is complex enough, how
much needs to be done in vitro prior to implantation,
whether inflammatory responses can be harnessed to en-
hance regeneration, and how to achieve integrative repair
in a diseased joint.
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